Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.77
    -0.59 (-0.71%)
     

  • GOLD FUTURES

    2,328.10
    -14.00 (-0.60%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,374.62
    -1,851.04 (-3.48%)
     

  • CMC Crypto 200

    1,377.55
    -46.55 (-3.27%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

FDA staff question dosing of Sanofi combination diabetes drug

Reuters - UK Focus

May 23 (Reuters) - A preliminary review by the U.S (Other OTC: UBGXF - news) . Food and Drug Administration questioned whether Sanofi SA's experimental drug lixisenatide contributed any benefit to a fixed-dose combination diabetes product the company hopes to market.

The review comes ahead of a May 25 meeting of an FDA advisory panel that will meet to discuss the drug and recommend whether it should be approved.

The FDA is not obliged to follow the recommendation of its advisory panels but typically does. On Tuesday the committee will consider a similar product made by Novo Nordisk (LSE: 0QIU.L - news) . (Reporting by Toni Clarke in Washington; Editing by Jeffrey Benkoe)